Biz News Today

Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference

November 10, 2009

Original Source

Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

November 10, 2009

Original Source

FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients

November 5, 2009

Original Source

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C

October 31, 2009

Original Source

Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond

October 29, 2009

Original Source

Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011

October 26, 2009

Original Source

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer

October 23, 2009

Original Source

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

October 22, 2009

Original Source

New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis

October 20, 2009

Original Source

ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)

October 19, 2009

Original Source

ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

October 5, 2009

Original Source

Study Finds That ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus

October 5, 2009

Original Source

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2009 on October 22

October 2, 2009

Original Source

Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin

October 2, 2009

Original Source

Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009

October 1, 2009

Original Source

Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible Notes

September 24, 2009

Original Source

Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

September 23, 2009

Original Source

Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk

September 15, 2009

Original Source

Bristol-Myers Squibb to Present at Morgan Stanley Global Healthcare Unplugged Conference

September 11, 2009

Original Source

Bristol-Myers Squibb Announces Dividend

September 9, 2009

Original Source

Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference

Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C

Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond

Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis

ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)

ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

Study Finds That ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2009 on October 22

Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin

Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009

Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible Notes

Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk

Bristol-Myers Squibb to Present at Morgan Stanley Global Healthcare Unplugged Conference

Bristol-Myers Squibb Announces Dividend

Biz News Today Accepts Guest Posts

Recommended Sites